awmsg logo



ramipril


Reference No. 1639

Publication date:
13/11/2012


Appraisal information

ramipril 2.5 mg/5 ml oral solution


Company: Rosemont Pharmaceuticals Ltd
BNF category: Cardiovascular system
NMG meeting date: 05/09/2012
AWMSG meeting date: 17/10/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2612
Ministerial ratification: 09/11/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Ramipril oral solution is recommended as an option for use within NHS Wales for: Treatment of hypertension. Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with: - manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease); - diabetes with at least one cardiovascular risk factor. Treatment of renal disease: - incipient glomerular diabetic nephropathy as defined by the presence of macroalbuminuria; - manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor; - manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day. Treatment of symptomatic heart failure. Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download